Romness Paul A. 4

What Happened

• Paul A. Romness, President & CEO and Director of OS Therapies (OSTX), was granted options to purchase 1,000,000 shares of the company's common stock. The grant is reported as a derivative award (transaction code A) with an acquisition price of $0.00 (the option grant itself required no cash payment on grant).
• Per the filing footnote, the options vest in full on the one‑year anniversary of the January 22, 2026 grant date, provided Romness remains an employee on that date. This is a compensation award (not an open‑market purchase or sale) and does not represent immediate share ownership or a cashless exercise.

Key Details

• Transaction date: January 22, 2026 (grant)
• Filing date: February 13, 2026 (Form 4) — the filing appears later than the typical 2 business‑day deadline for Form 4s.
• Instrument: Options to purchase 1,000,000 shares (derivative award, reported at $0.00 on grant)
• Vesting: 100% vesting on the one‑year anniversary of grant, conditional on continued employment (per footnote)
• Shares owned after transaction: Not specified in the provided filing summary
• Transaction code: A (award/grant)

Context

• These are stock options awarded as compensation; they are not exercisable into owned shares until vested and then only if the grantee pays the exercise price (if any) and satisfies other terms. The Form 4 shows the grant itself, not an exercise or sale.
• Awards like this are common for executive compensation; they differ from insider purchases (which can be viewed as a direct bullish signal) and from insider sales (which may be routine).
• The delayed filing may be administrative but can attract investor attention because Form 4s are expected within two business days of the transaction.